Compare CCM & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCM | PRPH |
|---|---|---|
| Founded | 1997 | 1989 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8M | 21.9M |
| IPO Year | 2009 | 1997 |
| Metric | CCM | PRPH |
|---|---|---|
| Price | $3.74 | $0.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.0K | ★ 2.8M |
| Earning Date | 09-26-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $51,056,841.00 | $5,055,000.00 |
| Revenue This Year | N/A | $221.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.60 | $0.13 |
| 52 Week High | $10.77 | $0.93 |
| Indicator | CCM | PRPH |
|---|---|---|
| Relative Strength Index (RSI) | 33.78 | 24.55 |
| Support Level | $3.71 | $0.16 |
| Resistance Level | $4.00 | $0.22 |
| Average True Range (ATR) | 0.21 | 0.04 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 10.68 | 3.34 |
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.